|Targets||c-Met/HGFR | VEGFR|
|Description||This active molecular is a c-MET and VEGFR inhibitor which is selective and specific in vitro. In vivo studies, TAS-115 suppressed the progression of MET-inactivated tumor completely through blocking angiogenesis without toxicity and it also induced marked tumor shrinkage and prolonged survival in animal model. In Dec 2013, Phase-I development was ongoing in Japan. In Dec 2014, Taiho Pharmaceutical completed a phase I trial for Solid tumours in Japan. In Apr 2016, preclinical data was presented.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator:Taiho Pharmaceutical|
SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...
(E)-FeCP-oxindole is a human vascular endothelial cell growth factor receptor 2 (VEGFR-2) inhibitor (IC50 = 214 nM). (E)-FeCP-oxindole exhibits anticancer activ...
Tepotinib, also known as EMD 1214063 and MSC2156119, is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibito...
SU 4312 is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 = 0.8 and 19.4 μM, respectively) wirth selectivity over EGFR and c-Src tyr...
ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2. The high efficacy, including tumour regression in established tum...
Aflibercept is a recombinant fusion protein and acts as a VEGF inhibitor. Aflibercept is used for the treatment of wet macular degeneration and metastatic color...
AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...
Motesanib is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors. It also pote...